# Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients

> **NCT05019040** · PHASE1,PHASE2 · COMPLETED · sponsor: **Zhejiang Palo Alto Pharmaceuticals, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Chronic HBV Infection

## Interventions

- **DRUG:** PA1010

## Key facts

- **NCT ID:** NCT05019040
- **Lead sponsor:** Zhejiang Palo Alto Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-17
- **Primary completion:** 2022-11-15
- **Final completion:** 2022-11-18
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05019040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05019040, "Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05019040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*